Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17784333 | 1.00 | POLB (0.42) | POLBTHRBGAAL3MBTL1MEN1 | |
| SCHEMBL17784334 | 1.00 | POLB (0.42) | POLBTHRBGAAL3MBTL1MEN1 | |
| SCHEMBL17784331 | 1.00 | POLB (0.42) | POLBTHRBGAAL3MBTL1MEN1 | |
| SCHEMBL8531037 | 0.70 | ALDH1A1 (0.47) | POLBTHRBGAAL3MBTL1SIGMAR1 | |
| SCHEMBL17190516 | 0.70 | SMN1; SMN2 (0.43) | POLBL3MBTL1MEN1KMT2ASIGMAR1 | |
| SCHEMBL17190503 | 0.70 | SMN1; SMN2 (0.43) | POLBL3MBTL1MEN1KMT2ASIGMAR1 | |
| SCHEMBL17784327 | 0.67 | MAPT (0.39) | POLBMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL8421338 | 0.66 | PTGS2 (0.48) | POLBMEN1KMT2ATP53AOC3 | |
| SCHEMBL2521501 | 0.66 | CTSD (0.49) | GAAL3MBTL1MEN1KMT2ASIGMAR1 | |
| SCHEMBL1766139 | 0.66 | CTSD (0.49) | GAAL3MBTL1MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160151505-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | KONINKLIJKE PHILIPS N.V. (NL) | 2016-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160151505-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | JMJD7, KIT, PAICS | POLB 2540/4885THRB 886/4885GAA 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.